{"id":502992,"date":"2021-06-11T07:34:12","date_gmt":"2021-06-11T11:34:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/"},"modified":"2021-06-11T07:34:12","modified_gmt":"2021-06-11T11:34:12","slug":"marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/","title":{"rendered":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences<\/b><\/p>\n<p>RADNOR, Pa.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmarinuspharma.com%2F&amp;esheet=52443715&amp;newsitemid=20210611005050&amp;lan=en-US&amp;anchor=Marinus+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=a324c25fd0436047d8a4c3cba6b2f1d7\">Marinus Pharmaceuticals, Inc.<\/a> (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences in June and July:\n<\/p>\n<p><span class=\"bwuline\">JMP Securities Life Sciences Conference<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Date and Time<\/b>: Thursday, June 17, 11:30 AM ET\n<\/li>\n<li><b>Speakers<\/b>: Scott Braunstein, M.D., Chief Executive Officer and Ian Miller, M.D., Vice President, Clinical Development\n<\/li>\n<li><b>Webcast Link<\/b>: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fjmp49%2Fregister.aspx%3Fconf%3Djmp49%26page%3Dmrns%26url%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fjmp49%2Fmrns%2F1705600&amp;esheet=52443715&amp;newsitemid=20210611005050&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Fjmp49%2Fregister.aspx%3Fconf%3Djmp49%26amp%3Bpage%3Dmrns%26amp%3Burl%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fjmp49%2Fmrns%2F1705600&amp;index=2&amp;md5=72a08ca31f7c1a1bb39ffd41ca1f32fa\">https:\/\/wsw.com\/webcast\/jmp49\/register.aspx?conf=jmp49&amp;page=mrns&amp;url=https:\/\/wsw.com\/webcast\/jmp49\/mrns\/1705600<\/a><\/li>\n<\/ul>\n<p><span class=\"bwuline\">SVB Leerink CNS Forum<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Date and Time<\/b>: Tuesday, June 29, 11:10 AM ET (open to Leerink clients only)\n<\/li>\n<li><b>Speakers<\/b>: Joe Hulihan, M.D., Chief Medical Officer and Henrikas Vaitkevicius, M.D. Vice President, Clinical Development\n<\/li>\n<li><b>Presentation Title<\/b>: \u201cA Discussion with Marinus Physicians About Status Epileptics\u201d\n<\/li>\n<\/ul>\n<p><span class=\"bwuline\">Ladenburg Thalmann 2021 Healthcare Conference<\/span><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Date and Time<\/b>: Wednesday, July 14, 11:30 AM ET\n<\/li>\n<li><b>Speakers<\/b>:<b \/>Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer\n<\/li>\n<li><b>Webcast Link: <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwsw.com%2Fwebcast%2Fladenburg7%2Fregister.aspx%3Fconf%3Dladenburg7%26page%3Dmrns%26url%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fladenburg7%2Fmrns%2F2449504&amp;esheet=52443715&amp;newsitemid=20210611005050&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Fladenburg7%2Fregister.aspx%3Fconf%3Dladenburg7%26amp%3Bpage%3Dmrns%26amp%3Burl%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fladenburg7%2Fmrns%2F2449504&amp;index=3&amp;md5=240d10cda4e84390209c8207d2116c0d\">https:\/\/wsw.com\/webcast\/ladenburg7\/register.aspx?conf=ladenburg7&amp;page=mrns&amp;url=https:\/\/wsw.com\/webcast\/ladenburg7\/mrns\/2449504<\/a><\/li>\n<\/ul>\n<p>\nAll of the above public webcasts may be accessed through the <i>Events &amp; Presentations<\/i> page of the <i>Investors &amp; Media<\/i> section of the Marinus website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52443715&amp;newsitemid=20210611005050&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=4&amp;md5=816143ce2ea411e0027cbfdfef37ab1e\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><b>About Marinus Pharmaceuticals<\/b><\/p>\n<p>\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA<sub>A<\/sub> receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex and has recently disclosed top-line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52443715&amp;newsitemid=20210611005050&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=5&amp;md5=1b20271ad23e225234abf536fc336687\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210611005050\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210611005050\/en\/<\/a><\/span><\/p>\n<p>\nSasha Damouni Ellis<br \/>\n<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>\n<br \/>Marinus Pharmaceuticals, Inc.<br \/>\n<br \/>484-253-6792<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sdamouni@marinuspharma.com\">sdamouni@marinuspharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Pennsylvania United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Biotechnology Other Health Health Pharmaceutical General Health Other Science Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210611005050\/en\/884579\/3\/FINAL_MARINUS_LOGO_USE_ON_ALL_MATERIALS_%281%29_%281%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences in June and July: JMP Securities Life Sciences Conference Date and Time: Thursday, June 17, 11:30 AM ET Speakers: Scott Braunstein, M.D., Chief Executive Officer and Ian Miller, M.D., Vice President, Clinical Development Webcast Link: https:\/\/wsw.com\/webcast\/jmp49\/register.aspx?conf=jmp49&amp;page=mrns&amp;url=https:\/\/wsw.com\/webcast\/jmp49\/mrns\/1705600 SVB Leerink CNS Forum Date and Time: Tuesday, June 29, 11:10 AM ET (open to Leerink clients only) Speakers: Joe Hulihan, M.D., Chief Medical Officer and Henrikas Vaitkevicius, M.D. Vice President, Clinical Development Presentation Title: \u201cA Discussion &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-502992","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences in June and July: JMP Securities Life Sciences Conference Date and Time: Thursday, June 17, 11:30 AM ET Speakers: Scott Braunstein, M.D., Chief Executive Officer and Ian Miller, M.D., Vice President, Clinical Development Webcast Link: https:\/\/wsw.com\/webcast\/jmp49\/register.aspx?conf=jmp49&amp;page=mrns&amp;url=https:\/\/wsw.com\/webcast\/jmp49\/mrns\/1705600 SVB Leerink CNS Forum Date and Time: Tuesday, June 29, 11:10 AM ET (open to Leerink clients only) Speakers: Joe Hulihan, M.D., Chief Medical Officer and Henrikas Vaitkevicius, M.D. Vice President, Clinical Development Presentation Title: \u201cA Discussion &hellip; Continue reading &quot;Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-11T11:34:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences\",\"datePublished\":\"2021-06-11T11:34:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/\"},\"wordCount\":420,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/\",\"name\":\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-06-11T11:34:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk","og_description":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences in June and July: JMP Securities Life Sciences Conference Date and Time: Thursday, June 17, 11:30 AM ET Speakers: Scott Braunstein, M.D., Chief Executive Officer and Ian Miller, M.D., Vice President, Clinical Development Webcast Link: https:\/\/wsw.com\/webcast\/jmp49\/register.aspx?conf=jmp49&amp;page=mrns&amp;url=https:\/\/wsw.com\/webcast\/jmp49\/mrns\/1705600 SVB Leerink CNS Forum Date and Time: Tuesday, June 29, 11:10 AM ET (open to Leerink clients only) Speakers: Joe Hulihan, M.D., Chief Medical Officer and Henrikas Vaitkevicius, M.D. Vice President, Clinical Development Presentation Title: \u201cA Discussion &hellip; Continue reading \"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-11T11:34:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences","datePublished":"2021-06-11T11:34:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/"},"wordCount":420,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/","name":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-06-11T11:34:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210611005050r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-present-at-multiple-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=502992"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/502992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=502992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=502992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=502992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}